Overview

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the effectiveness and safety of azacitidine in the treatment of Taiwanese subjects with higher-risk Myelodysplastic Syndrome (MDS).
Phase:
Phase 4
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Azacitidine
Molecular Mechanisms of Pharmacological Action